Mutations in a gene called CLN3 cause Batten disease, a rare and fatal neurodegenerative disorder of childhood. It is not a gene that anyone studies in inflammatory bowel disease.
It surfaced anyway. When researchers mapped how DNA folds within a scarce population of gut immune cells, CLN3 emerged as one of the genes whose variants associated with Crohn's disease risk appear to affect. The finding, published in Nature Genetics on Aug. 4, came from a team led by the MRC Laboratory of Medical Sciences in London, with Cincinnati Children's and collaborators across Europe and the United States.
The result depends entirely on a methodological workaround, and the workaround may end up mattering more than any single gene.
The Nearest Gene Is Often the Wrong Gene
Genome-wide association studies have identified thousands of DNA variants tied to common diseases. Most sit in regulatory stretches rather than in genes themselves, which leaves an obvious question: which gene is the variant actually acting on?
The default assumption has been the closest one. That assumption is frequently wrong because DNA is folded. Enhancers, the switches that boost gene activity in the right cell at the right moment, can sit thousands or even millions of DNA letters away from the genes they control and loop around to touch them.
"By mapping the 3D contacts between genes and enhancers, we can unlock the power of genome-wide association studies, implicating new genes and pathways in disease traits," said Mikhail Spivakov, head of the Functional Gene Control Group at the MRC laboratory, who led the study.
The complication is that folding differs by cell type. A variant might affect one gene in a blood cell and a different one in a gut cell, so a map built from whichever cells were easiest to collect can confidently point in the wrong direction.
The Cells Holding the Answers Are the Hardest to Get
For inflammatory bowel disease, one relevant cell type is the ILC3, a tissue-resident innate lymphoid cell that maintains gut barrier integrity and regulates inflammation.
ILC3s are rare and do not replicate well outside the body. Conventional Capture Hi-C, the technique Spivakov's group had used in earlier work on 3D genome folding, required millions of cells, putting ILC3s entirely out of reach.
Joint-first author Valeriya Malysheva, then a postdoctoral researcher in Spivakov's lab, developed a workaround called mini-Capture Hi-C that profiles DNA folding using dramatically fewer cells. When applied to human ILC3s isolated from tonsil tissue and compared with CD4 T cells, it produced a detailed map showing which enhancers physically contact which gene promoters.
Combined with large genome-wide association datasets and a Bayesian framework that weights multiple variants within a single region, the approach identified more than 100 candidate genes associated with Crohn's disease risk in ILC3s. About half had known roles in the disease. The rest did not. Extending the method to five additional immune traits revealed enrichment for regulators of ILC3 activation, according to the study.
The Batten Disease Gene, in Gut Immune Cells
CLN3 was the standout.
"Finding a neurological gene like CLN3 active in gut immune cells was a fascinating surprise," said Malysheva, now a fellow at the University of Cambridge and a group leader at the VIB Center for Molecular Neurology in Antwerp.
Joint first author Nora Lakes, a doctoral student at Cincinnati Children's, ran the validation. In a mouse ILC3-like cell line, expression of the mouse version of the gene decreased upon activation, and increasing its levels altered stimulation-induced transcription and cytokine secretion.
The researchers are explicit that this does not establish CLN3 as a causal gene in inflammatory bowel disease.
"We've shown that this gene regulates the inflammatory function of ILC3s, but it will take more research to establish exactly how this modulates Crohn's disease risk," said joint first author Helen Ray-Jones, based at Erasmus MC University Medical Center in Rotterdam.
What it does raise is a genuinely odd question about whether immune regulation and neurodegenerative disease pathways intersect. The team lists that as a research direction, not a conclusion.
Inflammatory bowel disease, of which Crohn's is a common form, affects around one in a hundred people globally and has no cure, according to the MRC laboratory, which is part of why unexplained genetic risk has drawn so much effort.
What Is Established and What Is Not
The mapping itself is the firm ground. The method works; it functions in cells previously out of reach and generates candidate genes that conventional nearest-gene reasoning would have missed.
Everything downstream is preliminary. The functional follow-up used a mouse cell line rather than patient samples. No treatment implication exists, and nothing here changes how Crohn's disease is diagnosed or managed.
"When you look at how the genome is wired in three dimensions, you start to see that genes linked to rare diseases, like CLN3, can have unexpected roles in immune cells," said Emily Miraldi of the divisions of Immunobiology and Biomedical Informatics at Cincinnati Children's.
The work was funded primarily by the Medical Research Council and the National Institutes of Health. The team's stated next steps include applying the technique to other rare immune cell types.
People with inflammatory bowel disease should discuss treatment questions with a gastroenterologist rather than drawing conclusions from early genetic research.
Key Questions Answered
What did the researchers do?
They used a miniaturized Capture Hi-C method to map long-range DNA interactions in ILC3s, a rare gut immune cell type, and then linked these maps to Crohn's disease risk variants.
Why was this hard before?
Conventional Capture Hi-C requires millions of cells. ILC3s are scarce and do not replicate well outside the body.
What is CLN3?
A gene whose mutations cause Batten disease, a rare fatal childhood neurodegenerative disorder. It has not typically been studied in the context of immune-driven disease.
Does CLN3 cause Crohn's disease?
No. The researchers state their findings do not establish it as a causal gene.
How many genes were identified?
More than 100 candidate genes linked to Crohn's disease risk in ILC3s, about half of them previously unassociated with the condition.
What was the functional evidence?
Experiments in a mouse ILC3-like cell line showed that altering the gene's expression changed transcription and cytokine secretion. No patient data were involved.
Does this change treatment?
No. It is basic genomic research with no immediate clinical application.
